Treace Medical lowers FY24 revenue guidance, stock price falls.

• Pomerantz LLP investigates Treace Medical for securities fraud claims. • Investors advised to contact Danielle Peyton or 646-581-9980. • Treace Medical lowers 2024 revenue guidance from $220-$225M to $201-$211M. • Competition from osteotomy and Lapiplasty "knockoffs" creates headwinds. • Stock price falls after earnings call on May 7, 2024.

New York, June 6, 2025 — Pomerantz LLP has announced an investigation into claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace Medical" or the "Company") (NASDAQ: TMCI). Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information.

The investigation concerns whether Treace Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. This comes after Treace Medical issued a press release after market hours on May 7, 2024, reporting a significant reduction in its full-year 2024 revenue guidance. The revenue guidance was lowered from between $220 million and $225 million to between $201 million and $211 million.

During the associated earnings call, the Company revealed that competition from minimally invasive osteotomy and Lapiplasty "knockoffs" was creating headwinds for its Lapiplasty growth. This revelation led to a substantial drop in the Company's stock price, which fell by $6.95, or nearly 63%, to close at $4.17 per share on May 8, 2024, on unusually high trading volume.

Investors who purchased or otherwise acquired Treace Medical securities during the Class Period have until June 10, 2025, to ask the Court to appoint them as Lead Plaintiff for the class. Those who wish to join the class action should contact Danielle Peyton at the aforementioned contact details.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.

References:
[1] https://www.morningstar.com/news/globe-newswire/9461729/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-treace-medical-concepts-inc-tmci
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-treace-medical-concepts-inc-of-class-action-lawsuit-and-upcoming-deadlines--tmci-302469067.html
[3] https://www.bakersfield.com/ap/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-treace-medical/article_0dd2c4a8-1531-5fa5-996d-2ace4a9f67c4.html
[4] https://www.morningstar.com/news/pr-newswire/20250601dc99110/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-treace-medical-concepts-inc-of-class-action-lawsuit-and-upcoming-deadlines-tmci
[5] https://www.globenewswire.com/news-release/2025/06/02/3092090/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-on-Behalf-of-Investors-of-Treace-Medical-Concepts-Inc-TMCI.html